100 related articles for article (PubMed ID: 31416848)
1. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
Haines K; Huang GS
Cancer Res; 2019 Aug; 79(16):4009-4010. PubMed ID: 31416848
[TBL] [Abstract][Full Text] [Related]
2. The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Taylor SE; O'Connor CM; Wang Z; Shen G; Song H; Leonard D; Sangodkar J; LaVasseur C; Avril S; Waggoner S; Zanotti K; Armstrong AJ; Nagel C; Resnick K; Singh S; Jackson MW; Xu W; Haider S; DiFeo A; Narla G
Cancer Res; 2019 Aug; 79(16):4242-4257. PubMed ID: 31142515
[TBL] [Abstract][Full Text] [Related]
3. Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D; Abbasi Asbagh L; Derua R; Hubert A; Schrauwen S; Hoorne Y; Amant F; Waelkens E; Sablina A; Janssens V
Cancer Res; 2016 Oct; 76(19):5719-5731. PubMed ID: 27485451
[TBL] [Abstract][Full Text] [Related]
4. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
5. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
6. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract][Full Text] [Related]
7. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM; Leonard D; Wiredja D; Avelar RA; Wang Z; Schlatzer D; Bryson B; Tokala E; Taylor SE; Upadhyay A; Sangodkar J; Gingras AC; Westermarck J; Xu W; DiFeo A; Brautigan DL; Haider S; Jackson M; Narla G
Oncogene; 2020 Jan; 39(3):703-717. PubMed ID: 31541192
[TBL] [Abstract][Full Text] [Related]
9. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
10. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
Jeong AL; Han S; Lee S; Su Park J; Lu Y; Yu S; Li J; Chun KH; Mills GB; Yang Y
Sci Rep; 2016 Jun; 6():27391. PubMed ID: 27272709
[TBL] [Abstract][Full Text] [Related]
11. PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.
Remmerie M; Janssens V
Front Oncol; 2019; 9():462. PubMed ID: 31214504
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A Aα regulates Aβ protein expression and stability.
O'Connor CM; Hoffa MT; Taylor SE; Avelar RA; Narla G
J Biol Chem; 2019 Apr; 294(15):5923-5934. PubMed ID: 30796164
[TBL] [Abstract][Full Text] [Related]
13. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
15. A Cancer-Associated Missense Mutation in PP2A-Aα Increases Centrosome Clustering during Mitosis.
Antao NV; Marcet-Ortega M; Cifani P; Kentsis A; Foley EA
iScience; 2019 Sep; 19():74-82. PubMed ID: 31357169
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Hanawa S; Mitsuhashi A; Shozu M
PLoS One; 2018; 13(2):e0192759. PubMed ID: 29444159
[TBL] [Abstract][Full Text] [Related]
17. Scaffold subunit Aalpha of PP2A is essential for female meiosis and fertility in mice.
Hu MW; Wang ZB; Jiang ZZ; Qi ST; Huang L; Liang QX; Schatten H; Sun QY
Biol Reprod; 2014 Jul; 91(1):19. PubMed ID: 24899574
[TBL] [Abstract][Full Text] [Related]
18. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Wang F; Zou Y; Liu FY; Yu XH; Huang H; Zhang N; Qi YY; Liu RF; Liu XY; Chen J; Huang OP; He M
Mol Med Rep; 2013 Jun; 7(6):1826-30. PubMed ID: 23588898
[TBL] [Abstract][Full Text] [Related]
19. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice.
Ruediger R; Ruiz J; Walter G
Mol Cell Biol; 2011 Sep; 31(18):3832-44. PubMed ID: 21791616
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
Remmerie M; Janssens V
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
